Publication: Plasma kininogen and kininogen fragments are biomarkers of progressive renal decline in type-1 diabetes
Open/View Files
Date
2013
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Merchant, Michael L., Monika Niewczas, Linda H. Ficociello, Janice Lukenbill, Daniel W. Wilkey, Ming Li, Syed J. Khundmiri, James H. Warram, Andrzej S. Krolewski, and Jon B. Klein. 2013. “Plasma kininogen and kininogen fragments are biomarkers of progressive renal decline in type-1 diabetes.” Kidney international 83 (6): 1177-1184. doi:10.1038/ki.2013.8. http://dx.doi.org/10.1038/ki.2013.8.
Research Data
Abstract
The ability of microalbuminuria to predict early progressive renal function decline in type-1 diabetic patients has been questioned. To resolve this, we determined the plasma proteome differences between microalbuminuric patients with type-1 diabetes and stable renal function (controls) and patients at risk for early progressive renal function decline (cases) and asked whether these differences have value as surrogate biomarkers. Mass spectrometry was used to analyze small (less than 3 kDa) plasma peptides isolated from well-matched case and control plasma obtained at the beginning of an 8-12 year follow-up period. Spearman analysis of plasma peptide abundance and the rate of renal function decline during follow-up identified seven masses with a significant negative correlation with early progressive renal function decline. Tandem mass spectrometry identified three fragments of high molecular weight kininogen. Increased plasma high molecular weight kininogen in the cases was confirmed by immunoblot. One peptide, des-Arg9-BK(1-8), induced Erk1/2 phosphorylation when added apically to two proximal tubular cell lines grown on permeable inserts. Thus, we have identified plasma protein fragments, some of which have biological activity with moderate to strong correlation, with early progressive renal function decline in microalbuminuric patients with type-1 diabetes. Other peptides are candidates for validation as candidate biomarkers of diabetes-associated renal dysfunction.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service